Immunome (NASDAQ:IMNM) Director Acquires $21,550.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 1,000 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were purchased at an average cost of $21.55 per share, with a total value of $21,550.00. Following the purchase, the director directly owned 38,415 shares of the company’s stock, valued at $827,843.25. The trade was a 2.67% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Immunome Trading Down 2.1%

Shares of IMNM opened at $21.40 on Thursday. The stock has a market capitalization of $2.42 billion, a P/E ratio of -8.84 and a beta of 2.12. The firm’s fifty day simple moving average is $22.75 and its two-hundred day simple moving average is $17.97. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, research analysts predict that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on IMNM. Craig Hallum raised their target price on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Evercore boosted their price target on Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, December 16th. HC Wainwright initiated coverage on Immunome in a report on Thursday, February 12th. They set a “buy” rating and a $40.00 price target on the stock. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Finally, Truist Financial assumed coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and an average target price of $33.45.

Hedge Funds Weigh In On Immunome

A number of hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Immunome by 44.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company’s stock worth $316,000 after purchasing an additional 14,398 shares during the last quarter. Teacher Retirement System of Texas boosted its position in shares of Immunome by 6.8% during the second quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after buying an additional 1,188 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Immunome by 16.8% during the second quarter. Los Angeles Capital Management LLC now owns 41,857 shares of the company’s stock valued at $389,000 after buying an additional 6,009 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new stake in Immunome during the second quarter worth $5,104,000. Finally, Geode Capital Management LLC grew its holdings in Immunome by 6.7% during the second quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after buying an additional 117,523 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.